Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)

Next Previous
Trial Profile

A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent HSV Vector Expressing the Human Collagen VII Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beremagene geperpavec (Primary)
  • Indications Epidermolysis bullosa dystrophica
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms GEM-1; GEM-2
  • Sponsors Krystal Biotech

Most Recent Events

  • 18 May 2026 According to a Krystal Biotech media release, company announced that on 15 MAY the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa based on results from GEM-1, GEM-3 studies and open label extension study and real-world experience with VYJUVEK..
  • 15 Sep 2025 According to a Krystal Biotech media release, the company announced that the US FDA approved a label update for VYJUVEK, expanding its use to dystrophic epidermolysis bullosa patients from birth and provides patients full flexibility with respect to VYJUVEK application and managing wound dressings. This label update is based on real-world data collected since VYJUVEK launch in US, and results from the open label extension study conducted in the US and published earlier this year.
  • 04 Aug 2025 According to a Krystal Biotech media release, VYJUVEK has been approved by European Commission (EC) for the treatment of wounds in patients with DEB.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top